Home

Hepion Pharmaceuticals, Inc. - Common Stock (HEPA)

0.3221
-0.0209 (-6.09%)
NASDAQ · Last Trade: Apr 18th, 4:49 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors
Hepion Pharmaceuticals (NASDAQ: HEPA) Reports Promising Phase 2 Trial Results for NASH Treatment
Renocofilstat's Positive Outcomes Reinforce Antifibrotic Action Hepion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on AI-assisted therapeutic drug development, recently
Via Spotlight Growth · May 22, 2023